SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused
on discovering, acquiring, developing and commercializing therapeutics
in the disease areas of immunology, inflammation and oncology, today
announced that it has filed a registration statement on Form S-1 with
the U.S. Securities and Exchange Commission (the “SEC”) in connection
with the commencement of a proposed initial public offering of its
common stock. Gossamer Bio is offering 14,375,000 shares of its common
stock at an initial public offering price of $16.00 per share. Gossamer
Bio has applied to list its stock for trading on the Nasdaq Global
Select Market under the symbol “GOSS.” Gossamer Bio expects to grant the
underwriters a 30-day option to purchase up to an additional 2,156,250
shares of common stock in connection with the offering. All of the
shares are being sold by Gossamer Bio.
Gossamer Bio has included in the registration statement the proposed
public offering price and the number of shares offered and specific
language under Rule 473(b) promulgated under the Securities Act of 1933,
as amended (the “Securities Act”), such that the registration statement
is expected to become automatically effective 20calendar
days after today’s filing, or February 12, 2019, pursuant to Section
8(a) of the Securities Act. Gossamer Bio expects to complete the pricing
of the offering on such date. In the event that the federal government
and the SEC resume normal operations prior to February 12, 2019,
Gossamer Bio will re-evaluate the use of Section 8(a) in connection with
the offering.
BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI are acting as
joint book-running managers for the proposed offering.
A registration statement relating to these securities has been filed
with the SEC, but has not yet become effective. These securities may not
be sold, nor may offers to buy be accepted, prior to the time the
registration statement becomes effective. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy, nor
shall there be any offer or sale of, these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of such
state or jurisdiction.
The proposed offering will be made only by means of a prospectus. Copies
of the preliminary prospectus relating to the proposed offering may be
obtained, when available, from: BofA Merrill Lynch, NC1-004-03-43, 200
North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department, or by email at dg.prospectus_requests@baml.com;
or from SVB Leerink, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by email at syndicate@leerink.com,
or by telephone at (800) 808-7525, ext. 6132; or from Barclays, c/o
Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long
Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or
by email at Barclaysprospectus@broadridge.com;
or from Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, or by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com.
Contacts
Gossamer Bio:
For Investors:
Argot Partners
Kimberly
Minarovich
Tel 212.600.1902
kimberly@argotpartners.com
For Media:
Argot Partners
David Rosen
Tel 212.600.1902
david.rosen@argotpartners.com
